EURORDIS - RARE DISEASES EUROPE

Their core work

EURORDIS is Europe's leading patient advocacy alliance for rare diseases, representing over 1,000 rare disease patient organizations across the continent. They bring the patient voice into drug development, clinical trial design, health technology assessment, and regulatory processes. Their work ensures that research programs, European Reference Networks, and policy frameworks account for the real needs of the 30 million Europeans living with rare conditions. They also drive data infrastructure and FAIR data principles to accelerate rare disease diagnosis and treatment.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), EURORDIS focused on adaptive regulatory pathways, reimbursement models, and multi-stakeholder collaboration for drug development — essentially shaping the policy environment for rare disease therapies. From 2019 onward, their focus shifted decisively toward data infrastructure, digital diagnostic tools, and clinical trial frameworks, with keywords like "FAIR data," "machine-learning," "newborn screening," and "clinical trial data reuse" dominating. This reflects a clear pivot from policy advocacy toward practical data-driven solutions for faster rare disease diagnosis and treatment access.

EURORDIS is moving rapidly into digital health infrastructure — genetic screening, AI-assisted diagnosis, and FAIR data ecosystems — making them an increasingly valuable partner for health-tech and data science consortia.

How they like to work

EURORDIS operates exclusively as a participant or partner, never as a coordinator — their role is to inject the patient perspective into large research consortia rather than to lead technical execution. With 317 unique partners across 37 countries, they are a major network hub in the rare disease ecosystem, connected to universities, hospitals, pharma companies, and regulators alike. Their consistent presence in large IMI and RIA consortia (often 20+ partners) makes them a reliable, well-connected consortium member who adds credibility and patient engagement capacity.

With 317 unique consortium partners spanning 37 countries, EURORDIS has one of the broadest collaborative networks in the rare disease space. Their reach is truly pan-European with connections extending well beyond Western Europe into associated countries.

What sets them apart

EURORDIS occupies a unique position as the bridge between the rare disease patient community and the research/regulatory establishment — no other European organization has this combination of legitimacy, scale, and institutional relationships. For consortium builders, adding EURORDIS means instant access to 1,000+ patient organizations, credibility with EMA and national agencies, and compliance with patient engagement requirements that are now mandatory in many EU funding calls. Their dual expertise in both policy frameworks and emerging data infrastructure makes them relevant to traditional health projects and to digital health innovation alike.

Highlights from their portfolio

• EJP RD
  Largest funding received (EUR 941,764) — a flagship European Joint Programme building shared rare disease research infrastructure, data platforms, and training across the continent.
• SCREEN4CARE
  Represents their emerging digital health direction — combines newborn genetic screening with machine-learning diagnostic tools, signaling EURORDIS's move into health-tech innovation.
• c4c
  Long-running project (2018–2025, EUR 653,750) building clinical trial infrastructure specifically for children — demonstrates their sustained commitment to underserved patient populations.